Intestinal Research

Toshihiro Inokuchi

4 Articles

IBD

The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces: Sakiko Hiraoka, Shiho Takashima, Toshihiro Inokuchi, Asuka Nakarai, Masahiro Takahara, Keita Harada, Yasuhiro Seki, Katsunori Watanabe, Jun Kato, Hiroyuki Okada; Intest Res 2019;17(2):202-209. Published online December 14, 2018; DOI: https://doi.org/10.5217/ir.2018.00086

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detecting activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance of simultaneous measurements of Fcal and FIT for ulcerative colitis (UC) patients using the newly-developed latex agglutination turbidimetric immunoassay (LATIA) system.
Methods
Fcal and hemoglobin were measured by the LATIA system in 152 UC patients who underwent colonoscopy. Fcal was also quantified with a conventional enzyme-linked immunosorbent assay (ELISA). Fecal markers were evaluated in conjunction with the mucosal status of UC, which was assessed via the Mayo endoscopic subscore (MES) classification.
Results
The LATIA system could quantify calprotectin and hemoglobin simultaneously with the same fecal samples within 10 minutes. The values of the Fcal-LATIA closely correlated with those of the Fcal-ELISA (Spearman rank correlation coefficient, r=0.84; P<0.0001). The values of Fcal for each assay and the FIT all significantly correlated with the MESs (Spearman rank correlation coefficient, Fcal-LATIA: r=0.58, Fcal-ELISA: r=0.55, and FIT: r=0.72). The mucosal healing predictability (determined by an MES of 0 alone) of the Fcal-LATIA, Fcal-ELISA, and FIT-LATIA with the cutoffs determined by receiver operating characteristic curve analysis was 0.79, 0.78, and 0.92 for sensitivity, respectively, and 0.78, 0.69, and 0.73 for specificity, respectively.
Conclusions
The performance of the novel Fcal-LATIA was equivalent to that of the conventional Fcal assay. Simultaneous measurements with FITs would promote the clinical relevance of fecal biomarkers in UC.

Citations

Citations to this article as recorded by

Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening
Timothy McAuliffe, Joseph C. Anderson, Robin J. Larson, Douglas J. Robertson
Alimentary Pharmacology & Therapeutics.2024; 59(9): 1033. CrossRef
Evaluation of a faecal calprotectin method using the OC-SENSOR PLEDIA
Shane O’Driscoll, Carolyn Piggott, Sally C. Benton
Clinical Chemistry and Laboratory Medicine (CCLM).2022; 60(6): 901. CrossRef
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
Ferdinando D'Amico, David T. Rubin, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Taku Kobayashi, Pablo A. Olivera, Peter Bossuyt, Lieven Pouillon, Edouard Louis, Eugeni Domènech, Subrata Ghosh, Silvio Danese, Laurent Peyrin‐Biroulet
United European Gastroenterology Journal.2021; 9(4): 451. CrossRef
Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis
Mariusz A. Bromke, Katarzyna Neubauer, Radosław Kempiński, Małgorzata Krzystek-Korpacka
Journal of Clinical Medicine.2021; 10(10): 2203. CrossRef
Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease
Eriko Yasutomi, Toshihiro Inokuchi, Sakiko Hiraoka, Kensuke Takei, Shoko Igawa, Shumpei Yamamoto, Masayasu Ohmori, Shohei Oka, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, Masaki Furukawa, Kouichi Itoshima, Ken Okada, Fumio Otsuka,
Scientific Reports.2021;[Epub] CrossRef
Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease
Eun Soo Kim
Gut and Liver.2021; 15(5): 637. CrossRef
Fecal calprotectin predicts complete mucosal healing in patients with ulcerative colitis: Systematic review and meta‑analysis
Zhongsheng Cao, Chenglong Ye, Lunan Li, Xiaoge Geng, Wensheng Pan, Jiyong Jing
World Academy of Sciences Journal.2021;[Epub] CrossRef
Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults
Małgorzata Krzystek-Korpacka, Radosław Kempiński, Mariusz Bromke, Katarzyna Neubauer
Diagnostics.2020; 10(6): 367. CrossRef
Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
Natsuki Ishida, Kiichi Sugiura, Takahiro Miyazu, Satoshi Tamura, Satoshi Suzuki, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Clinical and Translational Gastroenterology.2020; 11(12): e00289. CrossRef
Prediction of treatment outcome and relapse in inflammatory bowel disease
Jun Kato, Takeichi Yoshida, Sakiko Hiraoka
Expert Review of Clinical Immunology.2019; 15(6): 667. CrossRef

8,721 View
247 Download
9 Web of Science
10 Crossref

IBD

Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease: Shinichiro Shinzaki, Toshimitsu Fujii, Shigeki Bamba, Maiko Ogawa, Taku Kobayashi, Masahide Oshita, Hiroki Tanaka, Keiji Ozeki, Sakuma Takahashi, Hiroki Kitamoto, Kazuhito Kani, Sohachi Nanjo, Takeshi Sugaya, Yuko Sakakibara, Toshihiro Inokuchi, Kazuki Kakimoto, Akihiro Yamada, Hisae Yasuhara, Yoko Yokoyama, Takuya Yoshino, Akira Matsui, Misaki Nakamura, Taku Tomizawa, Ryosuke Sakemi, Noriko Kamata, Toshifumi Hibi; Intest Res 2018;16(4):609-618. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00044

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients.
Methods
IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians’ global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation.
Results
A total of 429 IBD (378 ulcerative colitis, 51 Crohn’s disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group: 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78–3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81–3.11; P=0.172]). Based on the physicians’ global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months’ observation period. The overall eradication rate was 84.0%–comparable to previous reports in non-IBD patients.
Conclusions
H. pylori eradication therapy does not alter the short-term disease activity of IBD.

Citations

Citations to this article as recorded by

Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry
Thu Giang Le Thi, Katharina Werkstetter, Kallirroi Kotilea, Patrick Bontems, José Cabral, Maria Luz Cilleruelo, Michal Kori, Josefa Barrio, Matjaž Homan, Nicolas Kalach, Rosa Lima, Marta Tavares, Pedro Urruzuno, Zrinjka Misak, Vaidotas Urbonas, Sibylle Ko
Helicobacter.2024;[Epub] CrossRef
Impact of Helicobacter pylori Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate?
Antonietta Gerarda Gravina, Raffaele Pellegrino, Veronica Iascone, Giovanna Palladino, Alessandro Federico, Rocco Maurizio Zagari
Diseases.2024; 12(8): 179. CrossRef
Bibliometric analysis of the correlation between H. pylori and inflammatory bowel disease
Yantong Li, Limin Li, Wenmeng Yin, Juyi Wan, Xiaolin Zhong
JGH Open.2024;[Epub] CrossRef
Discussion on the common controversies of Helicobacter pylori infection
Hang Yang, Yi Mou, Bing Hu
Helicobacter.2023;[Epub] CrossRef
Helicobacter pylori and Inflammatory Bowel Disease: An Unresolved Enigma
Juris Pokrotnieks, Stanislav Sitkin
Inflammatory Bowel Diseases.2023; 29(3): e5. CrossRef
Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems
Li Wang, Zheng-Min Cao, Li-Li Zhang, Xin-can Dai, Zhen-ju Liu, Yi-xian Zeng, Xin-Ye Li, Qing-Juan Wu, Wen-liang Lv
Frontiers in Immunology.2022;[Epub] CrossRef
Helicobacter pylori infection in patients with inflammatory bowel diseases: a single-centre, prospective, observational study in Egypt
Ekram W. Abd El-Wahab, Ebtessam I. Youssef, Ehab Hassouna
BMJ Open.2022; 12(5): e057214. CrossRef
Is the Presence of Helicobacter Pylori in the Colonic Mucosa, Provocative of Activity in Ulcerative Colitis?
Javad Ranjbar, Bita Geramizadeh, Kamran Bagheri Lankarani, Zahra Jowkar, Mitra Mirzai, Elham Moazamian
Clinical Pathology.2022;[Epub] CrossRef
Helicobacter pylori infection and inflammatory bowel diseases
Yu. P. Uspenskiy, N. V. Baryshnikova, A. N. Suvorov, A. V. Svarval
Russian Journal of Infection and Immunity.2021; 11(1): 68. CrossRef
Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer
Yuji Fujita, Keiichi Tominaga, Takanao Tanaka, Takeshi Sugaya, Shigemi Yoshihara
BMC Gastroenterology.2021;[Epub] CrossRef
Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with Helicobacter pylori infection and co-existing inflammatory bowel disease
Hussam Murad, Misbahuddin Rafeeq, Mahmoud Mosli, Mamdouh Gari, Mohammed Basheikh
Journal of International Medical Research.2021;[Epub] CrossRef
Extra-Gastric Manifestations of Helicobacter pylori Infection
Antonietta G. Gravina, Kateryna Priadko, Paola Ciamarra, Lucia Granata, Angela Facchiano, Agnese Miranda, Marcello Dallio, Alessandro Federico, Marco Romano
Journal of Clinical Medicine.2020; 9(12): 3887. CrossRef
Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance
Bekir Kocazeybek, Merve Kutlu Sakli, Pelin Yuksel, Mehmet Demirci, Reyhan Caliskan, Tevhide Ziver Sarp, Suat Saribas, Suleyman Demiryas, Fatma Kalayci, Huseyin Cakan, Hayriye Kirkoyun Uysal, Nesrin Gareayaghi, Sevgi Ergin, Yusuf Ziya Erzin, Kadir Bal, İhs
Journal of Medical Microbiology .2019; 68(4): 566. CrossRef
Review:Helicobacter pyloriand extragastric diseases
Francesco Franceschi, Marcello Covino, Claire Roubaud Baudron
Helicobacter.2019;[Epub] CrossRef

8,475 View
148 Download
15 Web of Science
14 Crossref

IBD

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease: Sakiko Hiraoka, Shiho Takashima, Yoshitaka Kondo, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Seiji Kawano, Keita Harada, Jun Kato, Hiroyuki Okada; Intest Res 2018;16(1):75-82. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.75

Abstract PDF PubReader ePub

<b>Background/Aims</b><br/>

The efficacy of anti-tumor necrosis factor α (anti-TNFα) antibodies for postoperative Crohn's disease (CD) in patients who were treated with these agents prior to surgery is largely unknown.

Methods

CD patients who underwent intestinal resection and received anti-TNFα agents after surgery were divided into 2 groups according to the presence or absence of preoperative anti-TNFα treatment: anti-TNFα restart group or anti-TNFα naïve group. Endoscopic recurrence after surgery was examined according to the preoperative conditions, including administration of anti-TNFα agents before surgery.

Results

Thirty-six patients received anti-TNFα antibody after surgery: 22 in the anti-TNFα restart group and 14 in the anti-TNFα naïve group. Endoscopic recurrence after surgery was more frequently observed in the anti-TNFα restart group than in the anti-TNFα naïve group (68% vs. 14%, P<0.001). Multivariate analysis revealed the following significant risk factors of endoscopic recurrence after surgery: anti-TNF restart group (odds ratio [OR], 28.10; 95% CI, 3.08–722.00), age at diagnosis <23 years (OR, 24.30; 95% CI, 1.67–1,312.00), serum albumin concentration at surgery <3.3 g/dL (OR, 34.10; 95% CI, 1.72–2,804.00), and presence of inflammation outside of the surgical site (OR, 21.40; 95% CI, 1.02–2,150.00). Treatment intensification for patients with endoscopic recurrence in the anti-TNFα restart group showed limited responses, with only 1 of 12 patients achieving endoscopic remission.

Conclusions

The efficacy of restarting anti-TNFα antibody treatment after surgery was limited, and treatment intensification or a change to different classes of biologics should be considered for those patients.

Citations

Citations to this article as recorded by

Influence of preoperative anti TNF alpha antibody therapy on postoperative recurrence of Crohn’s disease
Yuki Sekido, Takayuki Ogino, Takashi Takeda, Mitsunobu Takeda, Tsuyoshi Hata, Atsushi Hamabe, Hidekazu Takahashi, Norikatsu Miyoshi, Mamoru Uemura, Yuichiro Doki, Hidetoshi Eguchi, Tsunekazu Mizushima
Scientific Reports.2025;[Epub] CrossRef
Common Mistakes in Managing Patients with Inflammatory Bowel Disease
Javier P. Gisbert, María Chaparro
Journal of Clinical Medicine.2024; 13(16): 4795. CrossRef
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Javier P. Gisbert, María Chaparro
Drugs.2023; 83(13): 1179. CrossRef
Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
Nutrients.2023; 15(17): 3824. CrossRef
Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events
Mitchell R. K. L. Lie, Emma Paulides, C. Janneke van der Woude
International Journal of Colorectal Disease.2020; 35(8): 1489. CrossRef
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry
Fiorella Cañete, Míriam Mañosa, María José Casanova, Ramiro C González-Sueyro, Jesús Barrio, Fernando Bermejo, Pilar Nos, Eva Iglesias-Flores, Esther García-Planella, José Lázaro Pérez-Calle, Raquel Vicente, Maribel Vera, Laura Ramos, Montserrat Rivero, R
Inflammatory Bowel Diseases.2019; 25(11): 1862. CrossRef
Maneuvering Clinical Pathways for Crohn’s Disease
Thomas X. Lu, Russell D. Cohen
Current Gastroenterology Reports.2019;[Epub] CrossRef
Author's Reply
Sakiko Hiraoka, Jun Kato, Hiroyuki Okada
Intestinal Research.2018; 16(2): 321. CrossRef
The old versus the new: which do you keep in postoperative Crohn's disease?
Paulo Gustavo Kotze, Christopher Ma, Miguel Regueiro, Remo Panaccione
Intestinal Research.2018; 16(2): 319. CrossRef

5,568 View
84 Download
8 Web of Science
9 Crossref

Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?: Jun Kato, Sakiko Hiraoka, Asuka Nakarai, Shiho Takashima, Toshihiro Inokuchi, Masao Ichinose; Intest Res 2016;14(1):5-14. Published online January 25, 2016; DOI: https://doi.org/10.5217/ir.2016.14.1.5

Abstract PDF PubReader ePub

Accurate evaluation of disease activity is essential for choosing an appropriate treatment and follow-up plan for patients with inflammatory bowel disease (IBD). Endoscopy is required for accurately evaluating disease activity, but the procedures are sometimes invasive and burdensome to patients. Therefore, alternative non-invasive methods for evaluating or predicting disease activity including mucosal status are desirable. Fecal calprotectin (Fcal) is the most widely used fecal marker for IBD, and many articles have described the performance of the marker in predicting disease activity, mucosal healing (MH), treatment efficacy, and risk of relapse. Fecal immunochemical test (FIT) can quantify the concentration of hemoglobin in stool and was originally used for the screening of colorectal cancer. We recently reported that FIT is also a useful biomarker for IBD. A direct comparison between the use of Fcal and FIT showed that both methods predicted MH in ulcerative colitis equally well. However, in the case of Crohn's disease, FIT was less sensitive to lesions in the small intestine, compared to Fcal. FIT holds several advantages over Fcal in regards to user-friendliness, including a lower cost, easy and clean handling, and the ability to make rapid measurements by using an automated measurement system. However, there is insufficient data to support the application of FIT in IBD. Further studies into the use of FIT for evaluating the inflammatory status of IBD are warranted.

Citations

Citations to this article as recorded by

Delivery of Encapsulated Intelligent Engineered Probiotic for Inflammatory Bowel Disease Therapy
Zhen‐Ping Zou, Zhihao Cai, Xiao‐Peng Zhang, Donghui Zhang, Chu‐Ying Xu, Ying Zhou, Runhui Liu, Bang‐Ce Ye
Advanced Healthcare Materials.2025;[Epub] CrossRef
The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis
Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji, Behrad Saeedian, Tannaz Bagheri, Abdulrahman Ismaiel, Satohiro Matsumoto, Nastaran Babajani
European Journal of Gastroenterology & Hepatology.2025;[Epub] CrossRef
The synergy of dual faecal immunochemical and faecal calprotectin testing for accurate assessment of endoscopic and histological activity in inflammatory bowel disease
Anuj Bohra, Nicholas Batt, Krishneel Dutt, Diana Lewis, Jonathan P. Segal, Olga Newiadomski, Abhinav Vasudevan, Daniel R. Van Langenberg
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
Biomarkers in inflammatory bowel disease: a practical guide
Jennie Clough, Michael Colwill, Andrew Poullis, Richard Pollok, Kamal Patel, Sailish Honap
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
Multimodal Ultrasound Technology Combined with Fecal Calprotectin Assessment in Clinical Studies of Inflammatory Bowel Disease
泊辛陈
Advances in Clinical Medicine.2024; 14(07): 1110. CrossRef
Unraveling the intricacies of neutrophil extracellular traps in inflammatory bowel disease: Pathways, biomarkers, and promising therapies
Yilin Wu, Jun Shen
Cytokine & Growth Factor Reviews.2024; 80: 156. CrossRef
Positive Results from the Fecal Immunochemical Test Can Be Related to Dementia: A Nationwide Population-Based Study in South Korea
Yu Kyung Jun, Seung Woo Lee, Kwang Woo Kim, Jung Min Moon, Seong-Joon Koh, Hyun Jung Lee, Joo Sung Kim, Kyungdo Han, Jong Pil Im
Journal of Alzheimer's Disease.2023; 91(4): 1515. CrossRef
Fecal immunochemical test for haemoglobin versus fecal calprotectin to monitoring endoscopic activity in inflammatory bowel disease
Patricia Latorre Añó, Jorge Torrente Sánchez, Amparo Almudena Pérez Ibañez, Jose María Tenias Burillo, Nadia Paloma Moreno Sánchez, Antonio López-Serrano, Eduardo Moreno Osset, Julián Murado Pardo, José María Paredes
Revista Española de Enfermedades Digestivas.2023;[Epub] CrossRef
Tumorigenesis in Inflammatory Bowel Disease: Microbiota-Environment Interconnections
Irene Mignini, Maria Elena Ainora, Silvino Di Francesco, Linda Galasso, Antonio Gasbarrini, Maria Assunta Zocco
Cancers.2023; 15(12): 3200. CrossRef
Propensity score analysis the clinical characteristics of active distal and extensive ulcerative colitis: a retrospective study
Changchang Ge, Zhaofeng Shen, Yi Lu, Xiaojuan Liu, Yiheng Tong, Mengyuan Zhang, Yijing Liu, Hong Shen, Lei Zhu
Frontiers in Physiology.2023;[Epub] CrossRef
A unicentric cross-sectional observational study on chronic intestinal inflammation in total colonic aganglionosis: beware of an underestimated condition
M Erculiani, F Poluzzi, G Mottadelli, E Felici, Novi ML, M Caraccia, A Grandi, S Casella, L Giacometti, G Montobbio, I Ceccherini, E Di Marco, C Bonaretti, R Biassoni, M Squillario, A Pietrantoni, V Villanacci, A Pini Prato
Orphanet Journal of Rare Diseases.2023;[Epub] CrossRef
Fecal miR‐223 is a noninvasive biomarker for estimating Crohn's disease activity
Juanjuan Zhang, Zhen Guo, Zhiming Wang, Weiming Zhu, Qiurong Li
Immunity, Inflammation and Disease.2023;[Epub] CrossRef
Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis
Changchang Ge, Yi Lu, Hong Shen, Lei Zhu
Scandinavian Journal of Gastroenterology.2022; 57(5): 513. CrossRef
Efficacy of Fecal Calprotectin Combined With Stool Hemoglobin in Differentiating Bacterial Origin in Acute Gastroenteritis
Hyun Jin Kim
Pediatric Emergency Care.2022; 38(2): e670. CrossRef
Colorectal Cancer Screening in Inflammatory Bowel Diseases—Can Characterization of GI Microbiome Signatures Enhance Neoplasia Detection?
Molly Pratt, Jessica D. Forbes, Natalie C. Knox, Gary Van Domselaar, Charles N. Bernstein
Gastroenterology.2022; 162(5): 1409. CrossRef
Occult Blood in Feces Is Associated with Increased Risk of Psoriasis
Hyun Jung Lee, Kyungdo Han, Hosim Soh, Seong-Joon Koh, Jong Pil Im, Joo Sung Kim, Hyo Eun Park, Miri Kim
Dermatology.2022; 238(3): 571. CrossRef
Analytical evaluation of four faecal immunochemistry tests for haemoglobin
Carolyn Piggott, Magdalen R. R. Carroll, Cerin John, Shane O’Driscoll, Sally C. Benton
Clinical Chemistry and Laboratory Medicine (CCLM).2021; 59(1): 173. CrossRef
Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review
Monica State, Lucian Negreanu, Theodor Voiosu, Andrei Voiosu, Paul Balanescu, Radu Bogdan Mateescu
World Journal of Gastroenterology.2021; 27(16): 1828. CrossRef
Cost effectiveness of using Faecal Immunochemical Testing (FIT) as an initial diagnostic investigation for patients with lower gastrointestinal symptoms suggestive of malignancy
CC Kearsey, C Graham, HS Lobb, J Chacko, R Weatherburn, PS Rooney
BMC Family Practice.2021;[Epub] CrossRef
Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis
Natsuki Ishida, Satoru Takahashi, Yusuke Asai, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Immuno.2021; 1(4): 360. CrossRef
Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Bing-Jie Xiang, Min Jiang, Ming-Jun Sun, Cong Dai
Visceral Medicine.2021; 37(5): 338. CrossRef
Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease
Kohei Wagatsuma, Yoshihiro Yokoyama, Hiroshi Nakase
Life.2021; 11(12): 1375. CrossRef
Fecal calprotectin predicts complete mucosal healing in patients with ulcerative colitis: Systematic review and meta‑analysis
Zhongsheng Cao, Chenglong Ye, Lunan Li, Xiaoge Geng, Wensheng Pan, Jiyong Jing
World Academy of Sciences Journal.2021;[Epub] CrossRef
Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study
Eun Soo Kim, Hyun Seok Lee, Sung Kook Kim, Eun Young Kim, Byung Ik Jang, Kyeong Ok Kim, Chang Heon Yang, Yoo Jin Lee
Scandinavian Journal of Gastroenterology.2020; 55(2): 163. CrossRef
Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease
Jack S. Cornish, Elisa Wirthgen, Jan Däbritz
Frontiers in Medicine.2020;[Epub] CrossRef
Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker
Natsuki Ishida, Takahiro Miyazu, Tomoharu Matsuura, Ryosuke Takano, Satoshi Tamura, Takuma Kagami, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
International Journal of Colorectal Disease.2020; 35(9): 1729. CrossRef
Fecal MicroRNAs as Potential Biomarkers for Screening and Diagnosis of Intestinal Diseases
Humaira Rashid, Biplob Hossain, Towfida Siddiqua, Mamun Kabir, Zannatun Noor, Mamun Ahmed, Rashidul Haque
Frontiers in Molecular Biosciences.2020;[Epub] CrossRef
The association between fecal hemoglobin concentration and oral potentially malignant disorders
Amy Ming‐Fang Yen, Sen‐Te Wang, Sheng‐Wei Feng, Che‐Tong Lin, Sam Li‐Sheng Chen
Oral Diseases.2019; 25(1): 108. CrossRef
Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review
Joel Petit, Georgia Carroll, Tiffany Gould, Peter Pockney, Matthew Dun, Rodney J. Scott
Journal of Surgical Research.2019; 236: 184. CrossRef
Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations
Emilio J. Laserna-Mendieta, Alfredo J. Lucendo
Clinical Chemistry and Laboratory Medicine (CCLM).2019; 57(9): 1295. CrossRef
Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis
Jiajia Li, Xiaojing Zhao, Xueting Li, Meijiao Lu, Hongjie Zhang
Mediators of Inflammation.2019; 2019: 1. CrossRef
Predictors of mucosal healing during induction therapy in patients with acute moderate‐to‐severe ulcerative colitis
Maiko Motobayashi, Katsuyoshi Matsuoka, Kento Takenaka, Toshimitsu Fujii, Masakazu Nagahori, Kazuo Ohtsuka, Fumihiko Iwamoto, Kiichiro Tsuchiya, Mariko Negi, Yoshinobu Eishi, Mamoru Watanabe
Journal of Gastroenterology and Hepatology.2019; 34(6): 1004. CrossRef
Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis
Dae Gon Ryu, Hyung Wook Kim, Su Bum Park, Dae Hwan Kang, Cheol Woong Choi, Su Jin Kim, Hyeong Seok Nam
Medicine.2019; 98(36): e17080. CrossRef
Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta‐analysis
Cong Dai, Min Jiang, Ming‐Jun Sun, Qin Cao
Journal of Gastroenterology and Hepatology.2018; 33(5): 990. CrossRef
Monitoring Disease Activity: How and When?
Kang-Moon Lee
The Korean Journal of Gastroenterology.2018; 71(2): 69. CrossRef
An assessment of the effect of haemoglobin variants on detection by faecal immunochemical tests
Magdalen RR Carroll, Cerin John, Debbie Mantio, Natasha K Djedovic, Sally C Benton
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2018; 55(6): 706. CrossRef
Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis
Sakiko Hiraoka, Toshihiro Inokuchi, Asuka Nakarai, Shiho Takashima, Daisuke Takei, Yuusaku Sugihara, Masahiro Takahara, Keita Harada, Hiroyuki Okada, Jun Kato
Gut and Liver.2018; 12(2): 142. CrossRef
Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse
Asuka Nakarai, Sakiko Hiraoka, Sakuma Takahashi, Tomoki Inaba, Reiji Higashi, Motowo Mizuno, Shiho Takashima, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Keita Harada, Jun Kato, Hiroyuki Okada
Journal of Crohn's and Colitis.2018; 12(1): 71. CrossRef
Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores
Hai Yun Shi, Francis K. L Chan, Anthony W. H Chan, Akira Higashimori, Moe Kyaw, Jessica Y. L Ching, Arthur K. C Luk, Sunny H Wong, Justin C. Y Wu, Joseph J. Y Sung, Siew C Ng
Journal of Crohn's and Colitis.2017; 11(9): 1071. CrossRef
Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
The American Journal of the Medical Sciences.2017; 353(5): 439. CrossRef
Fecal calprotectin as a non‐invasive biomarker for intestinal involvement of Behçet's disease
Duk Hwan Kim, Yehyun Park, Bun Kim, Seung Won Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2017; 32(3): 595. CrossRef
Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease
Christopher Ma, Rowan Lumb, Emily V. Walker, Rae R. Foshaug, ThucNhi T. Dang, Sanam Verma, Vivian W. Huang, Karen I. Kroeker, Karen Wong, Levinus A. Dieleman, Richard N. Fedorak, Brendan P. Halloran
Inflammatory Bowel Diseases.2017; 23(9): 1643. CrossRef
Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization
Shuhei Fukunaga, Kotaro Kuwaki, Keiichi Mitsuyama, Hidetoshi Takedatsu, Shinichiro Yoshioka, Hiroshi Yamasaki, Ryosuke Yamauchi, Atsushi Mori, Tatsuyuki Kakuma, Osamu Tsuruta, Takuji Torimura
International Journal of Molecular Medicine.2017;[Epub] CrossRef
Fecal biomarkers in inflammatory bowel disease: how, when and why?
Paula Ministro, Diana Martins
Expert Review of Gastroenterology & Hepatology.2017; 11(4): 317. CrossRef
Assessment of disease activity by fecal immunochemical test in ulcerative colitis
Dae Gon Ryu, Hyung Wook Kim, Su Bum Park, Dae Hwan Kang, Cheol Woong Choi, Su Jin Kim, Hyeong Seok Nam
World Journal of Gastroenterology.2016; 22(48): 10617. CrossRef
Does Gastric Surgery (Such as Bariatric Surgery) Impact the Risk of Intestinal Inflammation?
Daniel Gero, Christian A. Gutschow, Marco Bueter
Inflammatory Intestinal Diseases.2016; 1(3): 129. CrossRef

7,466 View
106 Download
47 Web of Science
46 Crossref

Author index